Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC
January 16, 2026
Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.
- Buyers
- Zydus Lifesciences Limited, Zylidac Bio LLC
- Targets
- Agenus Inc.
- Sellers
- Agenus Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Genezen Acquires uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
July 1, 2024
Biotechnology
Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.
-
Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities
February 14, 2022
Biotechnology
Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.
-
Verdesian Life Sciences Acquires Cytozyme Laboratories
April 27, 2021
Agriculture
Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.
-
Intas Pharmaceuticals / Accord BioPharma Acquires UDENYCA Franchise from Coherus BioSciences
August 6, 2025
Pharmaceuticals
Intas Pharmaceuticals, via its U.S. specialty division Accord BioPharma, completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences. The asset sale expands Accord/Intas' FDA-approved biosimilar portfolio—particularly in oncology supportive care—and brings key Coherus commercial and manufacturing personnel into Accord to support continuity and growth in the U.S. and international markets.
-
Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.
January 29, 2021
Biotechnology
Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.
-
Lonza Group AG Acquires Synaffix B.V.
June 1, 2023
Biotechnology
Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.